COMMUNIQUÉS West-GlobeNewswire

Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
26/06/2026
SAN FRANCISCO and VANCOUVER, British Columbia, June 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in- [...]
Transcom Leading Voices Connects CX Executives Through Peer Learning
26/06/2026
Transcom opens Leading Voices, a platform of real-world advice from leaders working through AI adoption in customer experience. It pairs peer perspectives and learning tools with Transcom's own proven CX results, from [...]
Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker
26/06/2026
ALAMEDA, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today [...]
Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
26/06/2026
NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the [...]
New Autism Research to be Presented at European Purine Scientific Meeting
26/06/2026
CALGARY, Alberta, June 26, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF ), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company” ), a drug [...]
Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes
26/06/2026
WAYNE, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated [...]
CHMP recommendation advances Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab as a potential standard of care for relapsed/refractory multiple myeloma
26/06/2026
Recommendation supported by unprecedented Phase 3 data, demonstrating that TECVAYLI ® in combination with daratumumab achieved statistically significant improvements in progression-free and overall survival versus [...]
Elixirgen Therapeutics and Nippon Shinyaku Enter into an Option Agreement for the Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy
26/06/2026
BALTIMORE, June 26, 2026 (GLOBE NEWSWIRE) -- Elixirgen Therapeutics, Inc ., a clinical-stage biotechnology company developing treatments for rare diseases and aging-associated diseases, today announced that it has [...]
Complex Small Molecules Are Changing Drug R&D
26/06/2026
Structural complexity in modern small molecules is reshaping what drug development partners must deliver from discovery through commercial supply. Targeted protein degraders, covalent agents, and a new wave of kinase [...]
Hennick Humber Hospital Receives Milestone Grant from the Canadian Institutes of Health Research
26/06/2026
TORONTO, June 26, 2026 (GLOBE NEWSWIRE) -- The Research Team at Hennick Humber Hospital (HHH) has been awarded a major research grant from the Canadian Institutes of Health Research (CIHR) as part of a $10 million [...]
Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update
26/06/2026
Revenue increased by 107% year-over-year to $7.7 million in the full fiscal year 2026; increased revenue by 66% YoY in the fiscal fourth quarter 2026 The Company is transitioning its year-end from March 31 st to [...]
Idorsia confirms successful closing of Pharmakon loan agreement and full repayment of New Money Facility
26/06/2026
Allschwil, Switzerland – June 26, 2026 Idorsia Ltd (SIX: IDIA), a commercial-stage biopharmaceutical company with a portfolio of first- or best-in-class assets, today confirmed the successful closing of its previously [...]
Ligand Announces Closing of Convertible Senior Notes Offering
25/06/2026
Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution [...]
Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026
25/06/2026
COPENHAGEN, Denmark, June 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its clinical development programs for the treatment of children with achondroplasia [...]
Keros Therapeutics Appoints Anne Prener to its Board of Directors
25/06/2026
LEXINGTON, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE YEAR 2026 ENDED MARCH 31, 2026
25/06/2026
MINNEAPOLIS, MN, US, June 25, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV) (OTCID: PETVW), in cooperation with its wholly-owned subsidiaries, Cosmeta Corp, PetVivo Animal Health, Inc. and PetVivo AI, [...]
Eikon Therapeutics to Join the Russell 3000® Index
25/06/2026
Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the investment community MILLBRAE, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“ [...]
NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute
25/06/2026
WILMINGTON, Del., June 25, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx” or the “Company”) today issued the following statement in response to recent public claims made by Kadima [...]
TerrAscend Completes Oversubscribed Debt Financing, Raising $21.7 Million
25/06/2026
A portion of the proceeds were used to retire existing higher interest rate indebtedness with the remainder available for M&A TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- TerrAscend Corp. (the “Company”) (TSX: TSND) ( [...]

Pages